The role of sarcopenia in the development of non-alcoholic fatty liver disease
Open Access
- 14 November 2020
- journal article
- research article
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- Vol. 183 (11) , 70-73
Abstract
Currently, a large number of studies have been published supplementing our knowledge of sarcopenia and its effect on the development of metabolic disorders, including the formation of NAFLD. This data allows a new look at the pharmacological and non-pharmacological approaches to the treatment of NAFLD, based on basic physiological processes, including the biological axis of the muscle — the liver. This provides a compelling rationale for studying skeletal muscle as the main therapeutic target for NAFLD and metabolic syndrome.Keywords
This publication has 16 references indexed in Scilit:
- Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011)Journal of Hepatology, 2015
- Sarcopenia in liver cirrhosisEuropean Journal of Gastroenterology & Hepatology, 2015
- Which one is associated with nonalcoholic fatty liver disease? Small muscle mass or large fat massHepatology, 2014
- Presence of Sarcopenia (Muscle Wasting) in Patients With Nonalcoholic SteatohepatitisHepatology, 2013
- Relationship Between Sarcopenia and Nonalcoholic Fatty Liver Disease: The Korean Sarcopenic Obesity StudyHepatology, 2013
- Increasing muscle mass to improve metabolismAdipocyte, 2013
- Dynamics of the Skeletal Muscle Secretome during Myoblast DifferentiationMolecular & Cellular Proteomics, 2010
- Comparison of DXA and CT in the Assessment of Body Composition in Premenopausal Women With Obesity and Anorexia NervosaObesity, 2010
- Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 DiabetesDiabetes Care, 2010
- Prevalence of and Risk Factors for Nonalcoholic Fatty Liver Disease: The Dionysos Nutrition and Liver Study * #Hepatology, 2005